Diabetes and vascular disease: New therapeutic avenues

Vascul Pharmacol. 2023 Nov 28:107247. doi: 10.1016/j.vph.2023.107247. Online ahead of print.ABSTRACTVascular disease remains a major burden for people with type 2 diabetes due to the syndromic nature of the disease. Therefore, strategies that go beyond the mere glycemic control need to be enacted. Recent evidence has been gathered showing the cardiorenal potential of medications such as glucagon-like peptide1-receptor agonists (GLP1RA) and sodium-glucose transporter 2-inhibitors (SGLT2i). Even greater are the expectations for the new dual glucose-dependent insulinotropic-peptide (GIP) and GLP1 agonists. Along with these new diabetes drugs, opportunities are now provided for renal protecting agents like finerenone. Finally, new pharmacologic venues are currently under investigation for treating diabetic cardiomyopathy, a cause for heart failure in diabetes.PMID:38036017 | DOI:10.1016/j.vph.2023.107247
Source: Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research